Proteome Sciences, based in the U.K., is continuing to form partnerships for its PS Biomarker Services, the latest with Italian therapeutics company Siena Biotech. Proteome Sciences will be Sienna's "preferred supplier of protein and peptide biomarker services for its drug development programs," according to Genetic Engineering & Biotechnology News.
Proteome Sciences will help provide an analysis of "post-translational modifications" for a neurological disease-related protein, which would provide proof for a disease mechanism or action of a therapeutic. The report does not say which neurological disease is involved, although Siena Biotech is working on therapeutics for Huntington's and Alzheimer's diseases.
Proteome Sciences' PS Biomarker Services comprises a toolkit that measures and tests protein expression in disease and therapy. GEN reports that the deal with Siena follows shortly after Proteome signed R&D collaborations with the Buck Institute for Research on Aging and the Moffitt Cancer Center. Last September, Proteome Sciences announced a collaboration with Thermo Fisher Scientific to deliver products for protein biomarker research. Proteome is also working with Simon Lovestone at the Institute of Psychiatry at King's College London on a panel of 9 protein biomarkers for Alzheimer's.